Clinical Efficacy Evaluation and Mechanism Study of Anti-Hepatic Fibrosis Effectively Treated Prescription by Supplementing Deficiency and Clearing Collaterals
Phase 1
- Conditions
- liver fibrosis
- Registration Number
- ITMCTR2100005161
- Lead Sponsor
- Chengdu University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. Meet the diagnostic criteria for chronic hepatitis B fibrosis;
2. Diagnostic criteria of TCM syndrome of Qi deficiency and collateral obstruction;
3. Aged between 18-65 years old;
4. Good compliance and signed informed consent.
Exclusion Criteria
1. Those with poor compliance;
2. Those who are participating in other scientific research projects;
3. Diagnosed as severe chronic hepatitis B or prone to severe hepatitis;
4. Alcoholic, drug-related, infectious, hereditary, immune, and other viral liver diseases;
5. Decompensated patients after hepatitis;
6. Patients with severe heart, brain, lung and kidney diseases or tumors;
7. Pregnant women or lactating women; mentally ill or unable to cooperate.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method platelet;Hepatitis B core antibody;DNA;Hepatitis B E Antigen;Hepatitis B E antibody;total bilirubin;Aspartate aminotransferase;Alanine aminotransferase;Hepatitis B Surface Antigen;Hepatitis B Surface Antibody;
- Secondary Outcome Measures
Name Time Method